Filtered By:
Condition: Atrial Fibrillation
Countries: Japan Health
This page shows you your search results in order of relevance. This is page number 17.
Order by Relevance | Date
Total 333 results found since Jan 2013.
Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation
Conclusions PPI administration significantly decreased the trough and peak DCs in patients with NVAF. Therefore, when prescribing PPIs for patients with NVAF in a clinical setting, the possibility that the bioavailability of dabigatran may decrease should be considered.
Source: Journal of Arrhythmia - October 13, 2017 Category: Cardiology Source Type: research
The EXPAND study: Efficacy and safety of rivaroxaban in Japanese patients with non-valvular atrial fibrillation
The EXPAND study examined the real-world efficacy and safety of rivaroxaban for the prevention of stroke and systemic embolism (SE) in Japanese patients with non-valvular atrial fibrillation (NVAF).
Source: International Journal of Cardiology - February 3, 2018 Category: Cardiology Authors: Hiroaki Shimokawa, Takeshi Yamashita, Shinichiro Uchiyama, Takanari Kitazono, Wataru Shimizu, Takanori Ikeda, Masahiro Kamouchi, Koichi Kaikita, Koji Fukuda, Hideki Origasa, Ichiro Sakuma, Keijiro Saku, Yasuo Okumura, Yuichiro Nakamura, Hideo Morimoto, Na Source Type: research
The National Integrated Project for Prospective Observation of Non-communicable Disease and its Trends in the Aged 2010 (NIPPON DATA2010): Objectives, Design, and Population Characteristics.
CONCLUSIONS: We established NIPPON DATA2010 as a cohort study on a representative general Japanese population that covers all of Japan.
PMID: 29503381 [PubMed - in process]
Source: Journal of Epidemiology - March 7, 2018 Category: Epidemiology Tags: J Epidemiol Source Type: research
The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation
The objective of the study is to compare the effectiveness and safety of low-dose rivaroxaban to those of warfarin among Asians with NVAF.
Source: International Journal of Cardiology - March 14, 2018 Category: Cardiology Authors: Hsin-Fu Lee, Yi-Hsin Chan, Hui-Tzu Tu, Chi-Tai Kuo, Yung-Hsin Yeh, Shang-Hung Chang, Lung-Sheng Wu, Lai-Chu See Source Type: research
Minimally Invasive Mitral Valve Repair Through Right Minithoracotomy - 11-Year Single Institute Experience.
CONCLUSIONS: MIMVR can be performed safely with low levels of mortality and morbidity, and provides sufficient repair durability. A learning curve exists in terms of repair durability, especially for anterior mitral leaflet repair.
PMID: 29657253 [PubMed - as supplied by publisher]
Source: Circulation Journal - April 13, 2018 Category: Cardiology Authors: Sakaguchi T, Totsugawa T, Kuinose M, Tamura K, Hiraoka A, Chikazawa G, Yoshitaka H Tags: Circ J Source Type: research
The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation
The objective of the study is to compare the effectiveness and safety of low-dose rivaroxaban to those of warfarin among Asians with NVAF.
Source: International Journal of Cardiology - March 14, 2018 Category: Cardiology Authors: Hsin-Fu Lee, Yi-Hsin Chan, Hui-Tzu Tu, Chi-Tai Kuo, Yung-Hsin Yeh, Shang-Hung Chang, Lung-Sheng Wu, Lai-Chu See Source Type: research
Clinical characteristics and cardiovascular outcomes in patients with atrial fibrillation receiving rhythm-control therapy: the Fushimi AF Registry
AbstractManagement of atrial fibrillation (AF) with current rhythm-control therapy has an uncertain impact on outcomes. Among 3731 patients in the Fushimi AF Registry, a community-based prospective survey of AF patients in Fushimi-ku, Kyoto, we investigated the characteristics and outcomes in 478 patients receiving rhythm-control therapy (anti-arrhythmic drug and/or catheter ablation) alone, with 1279 patients receiving rate-control therapy (beta-blockers, calcium channel blockers, and digoxin) alone serving as a reference. The Rhythm-control group, 26% of which had prior catheter ablation, was younger (70.5 ± 10.8 v...
Source: Heart and Vessels - May 24, 2018 Category: Cardiology Source Type: research
Validation of Conventional Thromboembolic Risk Factors in a Korean Atrial Fibrillation Population - Suggestion for a Novel Scoring System, CHA2DS2-VAK.
CONCLUSIONS: Female sex was not associated with TE events in a Korean non-valvular AF population. The novel CHA2DS2-VAK scoring system, with substitution of CKD for female sex, might be more appropriate for the Korean population.
PMID: 30282848 [PubMed - as supplied by publisher]
Source: Circulation Journal - October 4, 2018 Category: Cardiology Authors: Cha MJ, Cho Y, Oh IY, Choi EK, Oh S Tags: Circ J Source Type: research
Safety of Anticoagulant Therapy Including Direct Oral Anticoagulants in Patients With Acute Spontaneous Intracerebral Hemorrhage.
CONCLUSIONS: Anticoagulant therapy was conducted for approximately 90% of anticoagulation-indicated patients after a median of 7 days from ICH onset. The predominant anticoagulant medications were DOACs. Anticoagulant therapy started from the acute phase of ICH should be safe.
PMID: 30587698 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 27, 2018 Category: Cardiology Authors: Sakamoto Y, Nito C, Nishiyama Y, Suda S, Matsumoto N, Aoki J, Shimoyama T, Kanamaru T, Suzuki K, Nishimura T, Mishina M, Kimura K Tags: Circ J Source Type: research
The Next Generation of Watchman Just Received CE Mark
Boston Scientific has just received the CE mark for the next generation Watchman FLX Left Atrial Appendage Closure (LAAC) device. The Marlborough, MA-based company said it has initiated a limited market release of the technology in Europe.
Watchman LACC devices are intended to reduce the risk of stroke in people with non-valvular Atrial fibrillation. The new Watchman FLX device was designed for simplified implantation to fit a wider range of patients, from those with simple to the most complex anatomies.
Boston Scientific said the device allows for implantation flexibility to customize placement with a fully enclosed and r...
Source: MDDI - March 14, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Source Type: news
Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - From the TWMU-AF PCI Registry.
CONCLUSIONS: Low-dose prasugrel, as part of triple therapy, did not increase the risk of bleeding compared with clopidogrel. Therefore, it can be an alternative to clopidogrel for patients with AF undergoing PCI.
PMID: 30918236 [PubMed - as supplied by publisher]
Source: Circulation Journal - March 26, 2019 Category: Cardiology Authors: Otsuki H, Yamaguchi J, Kawamoto T, Yoshikawa M, Ebihara S, Tanaka K, Nakao M, Jujo K, Arashi H, Ota Y, Saito K, Takagi A, Tanaka H, Fujii S, Honda A, Mori F, Hagiwara N Tags: Circ J Source Type: research
Worsening renal function, adverse clinical events, and major determinants for changes of renal function in patients with atrial fibrillation: a Japanese multicenter registry substudy.
Conclusion: Age ≥75 years, body weight ≤50 kg, a history of heart failure, and initially preserved renal function appear to promote renal dysfunction in patients with AF, but a history of AF ablation seems to have a favorable effect. Worsening renal function seems to increase AF patients' risk of adverse clinical events. Renal function can decline quickly; thus, early intervention including AF ablation is warranted.
PMID: 31204852 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 18, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research
Population Pharmacokinetics and Pharmacodynamics of Apixaban Linking Its Plasma Concentration to Intrinsic Activated Coagulation Factor X Activity in Japanese Patients with Atrial Fibrillation
In this study, we aimed to elucidate intrinsic factors affecting efficacy of apixaban by conducting population pharmacokinetic and pharmacodynamic analysis using data from 81 Japanese AF patients. The intrinsic FXa activity was determined to assess the pharmacodynamic effect of apixaban. The pharmacokinetic and pharmacodynamic profiles were described based on a one-compartment model with first-order absorption and a maximum inhibitory model, respectively. Pharmacokinetic and pharmacodynamic analysis was conducted using a nonlinear mixed effect modeling program. The population pharmacokinetic parameters of apixaban were fix...
Source: The AAPS Journal - June 23, 2019 Category: Drugs & Pharmacology Source Type: research
Clinical Profile of Thromboembolic Events in Patients With Hypertrophic Cardiomyopathy in a Regional Japanese Cohort - Results From Kochi RYOMA Study.
CONCLUSIONS: In this community-based registry, thromboembolic events were not rare in patients with HCM. All patients with HCM in whom AF develops should be given anticoagulation therapy regardless of their CHADS2score.
PMID: 31257313 [PubMed - as supplied by publisher]
Source: Circulation Journal - June 28, 2019 Category: Cardiology Authors: Hirota T, Kubo T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, Hamashige N, Yamamoto K, Kondo F, Bando K, Yamada E, Furuno T, Yabe T, Doi YL, Kitaoka H Tags: Circ J Source Type: research
Adverse Clinical Events during Long-Term Follow-Up After Catheter Ablation of Atrial Fibrillation.
This study aimed to investigate the discontinuation rate of anticoagulants and long-term incidence of strokes after PVI.We enrolled 512 consecutive Japanese patients with AF (mean age, 63.4 ± 10.4 years; 123 women; 234 with non-paroxysmal AF; CHADS2 score/CHA2DS2-VASC score, 1.32 ± 1.12/2.21 ± 1.54) who underwent PVI between 2012 and 2015. During a 28.0 ± 17.1 -month follow-up, anticoagulants were terminated in 230 (44.9%) of the 512 patients, AF recurred in 200 (39.1%), and 10 (1.95%) suffered from a stroke. Death occurred in 5 (0.98%) patients. Although the incidence of strokes, by a Kaplan-Meier analysis, was simila...
Source: International Heart Journal - July 18, 2019 Category: Cardiology Tags: Int Heart J Source Type: research
